Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
CNS Neurol Disord Drug Targets. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
PMCID: PMC2742220

Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial


Post mortem examinations of AN-1792-vaccinated humans revealed this therapy produced focal senile plaque disruption. Despite the dispersal of substantial plaque material, vaccination did not constitute even a partial eradication of brain amyloid as water soluble amyloid-β (Aβ) 40/42 increased in the gray matter compared to sporadic Alzheimer's disease (AD) patients and total brain Aβ levels were not decreased. Significant aspects of AD pathology were unaffected by vaccination with both vascular amyloid and hyperphosphorylated tau deposits appeared refractory to this therapy. In addition, vaccination resulted in the consequential and drastic expansion of the white matter (WM) amyloid pool to levels without precedent in sporadic AD patients.

Although vaccination disrupted amyloid plaques, this therapy did not enhance long-term cognitive function or necessarily halt neurodegeneration. The intricate involvement of vascular pathology in AD evolution and the firm recalcitrance of vessel-associated amyloid to antibody-mediated disruption suggest that immunization therapies might be more effective if administered on a prophylactic basis before vascular impairment and well ahead of any clinically evident cognitive decline. Amyloid-β is viewed as pathological based on the postmortem correlation of senile plaques with an AD diagnosis. It remains uncertain which of the various forms of this peptide is the most toxic and whether Aβ or senile plaques themselves serve any desirable or protective functions. The long-term cognitive effects of chronic immunotherapy producing a steadily accumulating and effectively permanent pool of disrupted Aβ peptides within the human brain are unknown. In addition, the side effects of such therapy provided on a chronic basis could extend far beyond the brain. Eagerly seeking new therapies, critical knowledge gaps should prompt us to take a more wholistic perspective viewing Aβ and the amyloid cascade as aspects of complex and many-faceted physiological processes that sometimes end in AD dementia.

An Alzheimer's disease (AD) diagnosis leaves patients with few treatment options and no hope of a cure. In light of this grim reality, the demonstration of senile plaque disruption through amyloid-β (Aβ) immunotherapy has been both stunning success and irresistible force. Despite the emergence of an unanticipated adverse event during the first human clinical trials [1], numerous new immuno-therapeutic approaches are undergoing evaluation. Although a clearly promising approach, several critical issues regarding the ultimate benefits and consequences of immune disruption of senile plaques remain unresolved.

It is widely accepted that in AD, senile plaques provoke deleterious responses and induce injury to surrounding neurons, so their prevention or removal would avert damage to surrounding tissue. Despite the fact that senile plaques are associated with pathological conditions, these deposits may actually represent the safest means to minimize the threats from excess production of potentially toxic soluble Aβ peptides [2-4]. An unanticipated consequence of liberating Aβ from plaques may be to grant these molecules easier access to compartments from which they had been safely excluded.

Immune Approaches to Amyloid Disruption

Antibodies binding the Aβ N-terminal region had been shown to disaggregate fibrillar amyloid in vitro [5]. The unequivocal demonstration by Schenk et al. [6] that immunizing a transgenic (Tg) mouse overexpressing a mutant amyloid-β precursor protein (AβPP) with Aβ42 could abolish or reduce amyloid pathology, initiated an extraordinary sequence of events that culminated in the vaccination of humans with early clinical signs of AD. This simple and counterintuitive therapy prevented or disrupted Aβ deposits and the generation of dystrophic neurites as well as the reactive astrocytosis typically distributed around senile plaques. Experiments with PDAPP Tg mice, aged to allow substantial amyloid deposits to form prior to vaccination, revealed that plaque burdens and pathology were significantly reduced, suggesting the treatment both disrupted and actually cleared the extant amyloid pathology from the brain.

Extending the vaccination strategy of Schenk et al. [6] to a variety of Tg mouse models resulted in the rapid and repeated demonstration of successful remediation of amyloid deposit pathology and reversal of cognitive deficits [7-10]. This response was also attainable by the simple passive infusion of antibodies in the periphery, suggesting that a fraction of the provided immunoglobulins crossed the blood-brain barrier to act in the brain tissue directly [11].

Human Ad and Animal Model Differences

The spectacular successes following Tg mouse Aβ vaccinations led to an extraordinarily rapid extrapolation to the human condition and clinical trials. But substantial differences exist between mice and humans in terms of lifespan, basic physiology and neuronal network complexity. Rodent neurons may exhibit greater resistance to stresses such as hypoxia and ischemia and assuming functional equivalence in responses between Tg mice and AD patients carries some risk. For example, mice have more than 75 known protease genes than humans even though the mouse genome is 14% smaller than the human genome [12,13]. In light of the fact that few comparable primate vaccination studies have been undertaken [14,15] and the second generation of clinical trials is already underway, we hope this well intended leap is successful.

Stained amyloid deposits created in many Tg mice bear a remarkable morphological resemblance to the senile plaques found in AD patients and recreate some of the neuropathology observed in AD. However, the systematic analysis and comparison of several mice strains engineered to overexpress human AβPP genes has revealed considerable heterogeneity between the various models in the expression of amyloid pathology [16-22]. Transgenic animals produce amyloid peptides that generally lack extensive post-translational modifications and are substantially more susceptible to disruption than Aβ species characteristic of human senile plaques. Whether these differences reflect the vastly different pace of amyloid evolution forced in Tg animals or more subtle underlying differences in biochemistry between human and rodent is unclear [18].

The Tg PDAPP mice over-expressing the mutant familial AD (FAD) AβPP 717 Val→Phe gene [23] have been widely employed as a model for amyloid deposition pathology. This rare mutation results in an early onset and aggressive dementia characterized, besides the generation of Aβ40 and Aβ42, by the production of longer Aβ peptides and unique flocculent plaques with a near total absence of classical senile plaques found in sporadic AD [24]. Detailed biochemical examination revealed PDAPP mice produce a unique, blended amyloid deposit pathology that is neither duplicated by other AβPP transgenic mice nor precisely characteristic of either FAD or sporadic AD [20]. Amyloid-β-like molecules with C-termini extending beyond the typical 40-42 amino acid end points as well as peptides with N-terminal truncations that are more soluble than sporadic AD species are produced in PDAPP mice [20]. In addition, AβPP proteolytic processing activities are altered resulting in the lack of normal fragments C-terminal (CT)83 and CT99 [20]. Despite these unique features, the rough equivalence in response of senile plaque structures to vaccination observed between PDAPP mice and AN-1792 vaccinated patients suggests these mice are a useful and practical model for evaluating treatments to reduce or prevent amyloid deposits in humans at the earlier stages of Alzheimer's dementia.

Although the pace and extent of vascular amyloid deposition differs between Tg mouse models [16-22], the amyloid present in this compartment neatly approximates that of human AD in its resistance to disruption by immunization.

Human Vaccination Outcomes

Detailed post mortem histological and biochemical examinations following AN-1792 vaccination of humans revealed a suite of changes similar to those observed in vaccinated Tg mice [25-30]. The degree of response to vaccination varied both according to the specific pathologic lesion and physical location.

a. Senile Plaques

Senile plaques were the most sensitive to immunologic disruption, with diffuse deposits apparently less susceptible and cerebrovascular amyloid refractory to this treatment [25-28]. These differential responses undoubtedly reflect the underlying amyloid species composition characteristic of each deposit type. Senile plaques were disrupted but not completely eradicated, with Ferrer et al. [26] observing the presence of abnormal “collapsed” plaques surrounded by microglia and multinucleated giant cells containing Aβ40/42 deposits. Nicoll et al. [29] observed “moth-eaten” plaque remnants and sparse residual dense plaque cores in three vaccinated patients while Patton et al. [28] described regions harboring possible plaque debris characterized by a small, central punctiform core surrounded by a halo of amyloid. The clear zone between core and halo exhibited no binding of anti-Aβ antibodies. Although the total amount of recoverable SDS-insoluble amyloid material was reduced substantially as a consequence of vaccination, MALDI-TOF mass spectrometry (MS) analysis of this material, that may correspond to the fibrillar remnants of collapsed plaques, revealed it contained a complex array of Aβ -derived peptides [28]. Senile plaque structure is complex [31] and it is possible that the Aβ remnants still microscopically observable in collapsed plaques simply represent a fraction of deposited amyloid that is associated with heterologous ancillary molecules and inaccessible to antibodies.

Interestingly, the vaccine-mediated disruption of senile plaque deposits was accompanied by a sharp increase in the amounts of water soluble Aβ40/42 present in the gray matter compared to the levels found in a group of sporadic AD patients [28]. This pool represents plaque-associated Aβ monomers and oligomers as well as molecules free in the interstitial fluid or cytosol. MALDI-TOF MS (Matrix-assisted laser desorption/ionization mass spectrometry) characterization revealed the presence of Aβ-derived peptides in this extract [28]. Even though remarkable senile plaque regression was observed in vaccinated patients, ELISA analyses revealed that the total Aβ levels in the brain gray matter did not exhibit a correlated and proportionate decrease. Instead, Aβ levels of vaccinated patients were increased in comparison to the ranges previously observed in AD patients [28]. This failure of disrupted Aβ to exit the brain was also observed in Tg mice [7,32]. MALDI-TOF MS analyses revealed that all the various amyloid-containing compartments, soluble, SDS-insoluble, vascular and WM, harbored a complex array of probable Aβ peptide-derived species exhibiting a variety of truncations at both the amino-and carboxyl-termini. Despite hydrolytic processing, these degraded remnants linger within the brain tissue and total net amyloid egress in these patients was apparently negligible.

b. Diffuse Amyloid

Diffuse amyloid deposits also exhibited a general, although not universal, pattern of focal depletion in response to AN-1792 vaccination [26-28]. In contrast to the reaction of senile plaques common in immunized patients [27,28], there was an apparent variable persistence of diffuse plaque structures. Patton et al., [28] were able to isolate substantial amounts of the most insoluble P3 component composed of Aβ 17-42 from both of two examined vaccinated cases. Studies of an AN-1792-immunized patient cohort by Hock et al. [33], revealed recognition of diffuse Aβ and vascular deposits, but the most avid binding activity was directed against senile plaques. An epitope mapping study of sera obtained from AN-1792-immunized patients, producing significant total titers, revealed that the induced antibodies primarily recognized the first ten N-terminal residues of the Aβ peptide [34]. This antibody binding profile in which the bulk of the antibody binding sites were located at the amino terminus of Aβ42 may partially explain the greater recalcitrance of diffuse amyloid deposits to disruption. N-terminal truncation of amyloid peptides deposited in human AD patients is substantial, suggesting the therapeutic benefits of antibodies targeting the amino terminus of Aβ would be limited [16,19]. Moreover, studies of antibodies produced in Aβ42 vaccinated mice directed against residues 4-10 primarily recognized amyloid plaques extant in human AD brain samples [35].

c. Vascular Amyloid

Substantial amounts of vascular amyloid persisted in senile plaque-depleted regions in every vaccinated patient examined [25-29]. Even though cortical and leptomeningeal vascular amyloid was resistant to disruption, vaccination produced substantial changes in these deposits which exhibited an apparent increase in severity and molecular composition complexity [25,28]. The elevated cortical and leptomeningeal vascular Aβ42 levels [26,28], combined with the presence of an uncharacteristically rich spectrum of Aβ degradation products revealed by MALDI-TOF MS suggests the amyloid molecules mobilized out of senile plaques were subsequently retained in the vasculature. Given its intrinsically greater toxicity, the long-term effects of shifting the balance of vascular amyloid pools toward Aβ42 and/or degraded or post-translationally modified species may be deleterious.

d. White Matter

The WM does not exhibit the spectacular pathologic lesions such as senile plaques and neurofibrillary tangles (NFT) found in the gray matter, but this crucial compartment is affected in AD and was drastically altered after AN-1792 vaccination. Nicoll et al., [25] noted substantial WM atrophy and pathologic inflammatory alterations and Ferrer et al., [26] found extensive demyelination in the frontal lobe WM in a vaccinated patient. A broad range of structural changes in WM is a common feature of AD [36,37]. Although no pathological alteration in the WM is directly attributable to Aβ, elevated levels of soluble oligomers or other species are present in AD patients, suggesting that this compartment is a sink for Aβ synthesized in the gray matter or elsewhere [36]. The total Aβ40 and Aβ42 increased dramatically in vaccinated patients to amounts far beyond the elevated levels typical of sporadic AD cases. The fact that MALDI-TOF MS experiments revealed an extraordinary range of probable amyloid-derived species, many of which exhibited post-translational modifications like those of cortical Aβ, suggests that the WM was an ultimate sink for mobilized senile plaque molecules. Given that the majority of sporadic AD patients exhibit a broad range of profound pathological changes in WM structure [25,26,36,37], this outcome is worrisome.

e. Tau and NFT Pathology

The AN-1792 vaccination induced marked changes in amyloid deposition patterns, but exerted a comparatively minor impact on tau-mediated pathologic lesions [25-29]. Ferrer et al. [26] and Nicoll et al. [29] noted that while areas with intact neuritic plaques also harbored phosphorylated tau similar to that found in AD patients, amyloid plaque-depleted regions contained collapsed plaques with almost no tau-reactive neurites, but NFT and neuritic threads were unaffected and still present. Additional postmortem examinations conducted by other groups noted a similar pattern of regions in which amyloid plaques and diffuse deposits were apparently depleted while NFT remained in place, largely untouched in the face of such drastic amyloid pathological lesion alterations [27,28]. Triple Tg mice exhibiting both plaques and NFT subjected to anti-Aβ immunotherapy or a γ-secretase inhibitor revealed marked tau and amyloid deposit reductions. However, remediation of tau pathology by these methods was only partially effective, with hyperphosphorylated tau aggregates appearing impervious to disruption [38]. Immunotherapy of the same Tg mice with an anti-tau antibody failed to exert any detectable effects on tau or Aβ pathology [38].

Individuals immunized with AN-1792 exhibited mild to moderate dementia, meaning that this intervention occurred relatively early in the clinical progression of AD. In spite of early application of immunotherapy and the dependence of tau-associated pathology on Aβ, this intervention was not quick enough to prevent an effectively irreversible NFT evolution. Neurofibrillary tangles and neuropil threads are correlated with the cognitive impairment of AD and the persistence of these lesions in the face of anti-Aβ vaccination has led to suggestions that earlier interventions may be more efficacious [39]. Certainly the tenacity of these dementia-linked lesions complicates clinical assessments of cognitive improvements that follow anti-amyloid immunotherapy. Perhaps unless vaccination is offered before NFT become numerous, the best outcome associated with this therapy could be a marked slowing or halting of dementia progression.

Adverse Events and New Animal Model Experiments

Although vaccinating PDAPP and other Tg mice against Aβ initially appeared successful and without overt toxicity, the rapid development of aseptic meningoencephalitis in some of the AN-1792-vaccinated patients led to an early suspension of that trial [1]. Later studies examining both active and passive immunization revealed the potential for the development of reactive autoimmune encephalomyelitis in mice [40,41]. Given this lack of equivalence between humans and mice, examinations of other model systems have been undertaken. Non-human primates may provide more faithful models of the type of immune responses elicited in aging AD patients [14]. Studies of Caribbean Vervets revealed an age-dependent deposition of amyloid and associated neurodegeneration which was subjected to modulation by vaccination [15]. Canines accumulate diffuse amyloid plaques with age and exhibit correlated cognitive declines and a recent long-term study of Aβ42-immunized dogs revealed deposits were reversed, but found no improvement in cognition [42]. The authors suggest that earlier intervention before amyloid pathology is developed may result in an improved cognitive status. This outcome parallels the results with AN-1792-vaccinated humans in which evidence for decisive cognitive improvements is equivocal.

Vaccination and Cognition

A follow-up study of AN-1792-immunized patients confirmed to generate anti-Aβ antibodies showed these patients exhibited significantly slower decline in cognition and functional decline rates [43] while a 12 month follow-up study conducted by Gilman et al. [44] was not as clear. A recent long-term study of eight select AN-1792-immunized patients who died with AD suggests that although vaccination disrupted amyloid plaques, this therapy did not enhance cognitive function or necessarily halt neurodegeneration [30]. Volumetric MRI studies of AN-1792 vaccination responders revealed that this group had significantly greater volume decreases and ventricular enlargement than control patients, although the losses were not correlated with more severe cognitive declines [45]. A later study specifically investigating the relationship between Aβ burden and brain atrophy found that total Aβ levels were not linked to rates of brain loss or ventricular expansion [46]. The fact that AD dementia is a complex melange of underlying toxic effects ascribable to both amyloid and NFT pathology, as well as other idiosyncratic factors related to aging, confounds any simple interpretation of an experimental outcome.

Assessing the Case for Early Intervention

The intricate involvement of vascular pathology in AD evolution and the firm recalcitrance of vessel-associated amyloid to antibody-mediated disruption suggest that immunization therapies would be most effective if administered on a prophylactic basis before vascular impairment and well ahead of any clinically evident cognitive decline. The results of experiments with Tg mice and the first clinical trial clearly support this general idea [6,7,11,25-29,47]. Deploying anti-Aβ vaccines prior to the onset of any evidence of dementia is not feasible at present. However, Klunk et al. [48] have pointed out that FAD gene carriers represent an extraordinary valuable resource for the clinical evaluation of amyloid disrupting therapies. If voluntary and preemptive vaccination of known FAD gene carriers either staves off the onset of dementia or prevents it in such patients, the case for similar approach against sporadic AD will be virtually irresistible. Alzheimer's disease pathology is presumed to require extended periods to develop, but recent studies in Tg mice suggest that under the proper conditions senile plaques seed quickly [49]. Pathological signs of this emergence may be too subtle to be easily detected, increasing the need for preventative therapies. Preliminary results from phase II clinical trials with the humanized monoclonal antibody bapineuzumab suggest that apolipoprotein E (ApoE) genotype influences safety and efficacy (Alzheimer Research Forum Carriers of ApoE ε4 allele had more serious adverse events and did not exhibit clear cut improvements. These findings underscore the complex nature of AD pathology and the risks inherent in preventative therapies ultimately applied to a diverse population.

Amyloid-β is viewed as pathological based on the postmortem correlation of senile plaques with an AD diagnosis. However, the recent follow-up study of eight AN-1792-immunized patients of Holmes et al. [30] suggests that senile plaque disruption may not halt disease progression. It remains uncertain which of the various forms of this peptide is the most toxic and whether Aβ performs any desirable or protective functions. Perhaps Aβ molecules maintain the vascular integrity with or without recourse to blood coagulation by functioning as rapid sealants and thereby prevent conditions that could lead to neuronal injury [50]. This suggests that immunotherapy that is too effective at removing and/or preventing Aβ deposits could pose risks to the vasculature, an outcome that has been observed in immunized Tg mice [51,52]. In APP23 and the double transgenic APP/PS1 mice which produce a substantial vascular amyloid pathology, anti-Aβ immunotherapy resulted in increased rates of micro-hemorrhages [51,52]. The long-term cognitive effects of chronic immunotherapy producing a steadily accumulating and effectively permanent pool of disrupted Aβ peptides within the human brain are unknown. The fact that vaccination of Tg animals produces measurable cognitive improvements [7,32,53], despite the persistence of Aβ, is of relevance to the human condition only if rodent and human neurons react to amyloid and vascular pathology in an equivalent manner. It must be remembered that the Tg mice amyloid deposition models lack the full spectrum of biochemical and pathological conditions that will co-exist in the typical human AD patient. This complicates all attempts to extrapolate experimental results in animals to the human condition directly.

Amyloid-β released from plaques apparently did not exit the brain of immunized patients [28], paralleling results obtained with some Tg mice models [7,47]. If senile plaques are actually a mechanism to sequester potentially toxic Aβ molecules [3,4] disturbing these structures may pose unanticipated risks over the long term. Despite its strong conservation over great phylogenetic distances [18], the physiological functions of Aβ are still unclear. A largely neglected corpus of evidence compiled and reviewed by Heininger [4,54] calls attention to the potent physiological and metabolic effects exerted by Aβ and their potential adaptive significance to a brain confronting age-related circulatory insufficiency, energy deprivation and consequent metabolic stress. Active Aβ immunotherapy perturbed fundamental tissue fluid dynamics to such an extent that unprecedentedly high levels of Aβ were detected in the white matter [28]. As it stands, immunotherapy may not represent an AD cure; it simply changed the physical state of Aβ and transferred a considerable fraction of the disrupted amyloid deposit molecules to different brain compartments [28].

Approaches utilizing passive immunization have been examined in clinical trials. Intravenous immunoglobulin (IVIg) contains anti-Aβ antibodies and a short term study in a small number of early stage patients revealed proportionately increased levels of both specific antibodies and Aβ in plasma [55]. In addition, cerebrospinal fluid Aβ levels decreased with administration of IVIg and fluctuated in step with the presence of exogenous anti-Aβ antibodies. Most important, Mini-Mental State Examination scores increased with initial IVIg administration, returned to original levels as Aβ antibodies declined and stabilized with additional IVIg infusion. This was a short term and small scale study that will require further investigation.

Although antibodies are therapeutic tools of extraordinary precision, inducing or administering immunoglobulins in the periphery to effect a change within the CNS is considerably less focused. The side effects of such therapy, which could extend far beyond the brain, are uncertain. A concerted effort to detect and evaluate long-term adverse reactions in the periphery must be undertaken in Tg mice and other models. Given the potential of Aβ to impact a substantial range of processes, it seems wise to scrutinize all study participants for their state of health across many parameters beyond simply seeking to assess cognitive status. One issue that must be clarified is the overall level of amyloid in the periphery to act as a sink for antibody. Since only a small fraction of the immunoglobulin present in the circulation will ever enter the brain, maintaining high total antibody titers for the longest possible intervals is essential and may be confounded by the presence of sizeable antibody sinks at other locations.

Dementia is a relentlessly progressive process of multiple years duration that is only partly correlated with senile plaques. The fact that certain FAD patients exhibit aggressive and early-onset dementias with amyloid deposition patterns that differ from sporadic AD [56] further emphasizes the comparatively weak link between senile plaques and cognitive impairment. In addition, postmortem examinations revealed consistently that NFT pathologic alterations were unaffected by Aβ vaccination [25-29]. Taken together, AN-1792 follow-up studies of immunized patients have suggested that even extensive senile plaque disruption might yield at best only modest and temporary clinically quantifiable cognitive improvement [30,43,44]. These findings remind us to take a more synthetic view of Aβ and the amyloid cascade as one aspect of a complex and many-faceted process that ends in AD dementia. Assessment of the outcome of vaccination will help clarify the importance of the amyloid cascade to AD dementia. Although many recipients of the original vaccine have now survived for years, passive immunotherapy performed on a chronic basis promises even more effective amyloid disruption across a greater range of patients. This approach to disrupting amyloid deposits may well be efficient, but only time will reveal if it is wise.


This study was supported by The National Institute on Aging ROl-AG-19795, The Arizona Alzheimer's Disease Core Center NIA P30 AG-19610 and the State of Arizona Alzheimer's Disease Research Consortium.


Amyloid-β precursor protein
Alzheimer's disease
Apolipoprotein E
Familial Alzheimer's disease
Intravenous immunoglobin
Matrix-assisted laser desorption/ionization mass spectrometry
Neurofibrillary tangles
White matter


1. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46–54. [PubMed]
2. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077–81. [PubMed]
3. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem. 1996;271:20631–35. [PubMed]
4. Heininger K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum Psychopharmacol. 2000;15:1–70. [PubMed]
5. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997;94:4109–12. [PubMed]
6. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–7. [PubMed]
7. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979–82. [PubMed]
8. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982–5. [PubMed]
9. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850–5. [PubMed]
10. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA. 2004;101(Suppl 2):14657–62. [PubMed]
11. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9. [PubMed]
12. Puente XS, Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res. 2004;14:609–22. [PubMed]
13. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet. 2003;4:544–58. [PubMed]
14. Gandy S, Walker L. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates. Curr Opin Immunol. 2004;16:607–15. [PubMed]
15. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283–97. [PubMed]
16. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem. 2001;276:12991–8. [PubMed]
17. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med. 2001;7:609–18. [PMC free article] [PubMed]
18. Roher AE, Kokjohn TA. Of mice and men: the relevance of transgenic mice Abeta immunizations to Alzheimer's disease. J Alzheimer's Dis. 2002;4:431–4. [PubMed]
19. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002;41:922–8. [PubMed]
20. Esh C, Patton L, Kalback W, Kokjohn TA, Lopez J, Brune D, Newell AJ, Beach T, Schenk D, Games D, Paul S, Bales K, Ghetti B, Castano EM, Roher AE. Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry. 2005;44:13807–19. [PubMed]
21. Van Vickie GD, Esh CL, Kalback WM, Patton RL, Luehrs DC, Kokjohn TA, Fifield FG, Fraser PE, Westaway D, McLaurin J, Lopez J, Brune D, Newel AJ, Poston M, Beach TG, Roher AE. TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation. Biochemistry. 2007;46:10317–27. [PubMed]
22. Van Vickie GD, Esh CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Walker DG, Lue LF, Beach TG, Davis J, Van Nostrand WE, Castano EM, Roher AE. Tg-SwDl transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am J Pathol. 2008;173:483–93. [PubMed]
23. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523–7. [PubMed]
24. Roher AE, Kokjohn TA, Esh C, Weiss N, Childress J, Kalback W, Luehrs DC, Lopez J, Brune D, Kuo YM, Farlow M, Murrell J, Vidal R, Ghetti B. The human amyloid-beta precursor pro- tein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. J Biol Chem. 2004;279:5829–36. [PubMed]
25. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448–52. [PubMed]
26. Ferrer I, Boada RM, Sanchez GML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11–20. [PubMed]
27. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129–31. [PubMed]
28. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickie GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castano EM, Roher AE. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006;169:1048–63. [PubMed]
29. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040–8. [PubMed]
30. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–23. [PubMed]
31. Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 1993;61:1916–26. [PubMed]
32. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452–7. [PubMed]
33. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8:1270–5. [PubMed]
34. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol. 2005;58:430–5. [PubMed]
35. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Home P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263–9. [PubMed]
36. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T. Increased Abeta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry. 2002;41:11080–90. [PubMed]
37. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med. 2003;9:112–22. [PMC free article] [PubMed]
38. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321–32. [PubMed]
39. Greenberg SM, Bacskai BJ, Hyman BT. Alzheimer disease's double-edged vaccine. Nat Med. 2003;9:389–90. [PubMed]
40. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 2003;126:285–91. [PubMed]
41. Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 2005;579:2564–8. [PubMed]
42. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci. 2008;28:3555–66. [PubMed]
43. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547–54. [PubMed]
44. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–62. [PubMed]
45. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN 1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563–72. [PubMed]
46. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR., Jr Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204–12. [PMC free article] [PubMed]
47. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abetal-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001;22:721–7. [PubMed]
48. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174–84. [PMC free article] [PubMed]
49. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720–4. [PMC free article] [PubMed]
50. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. Beta-amyloid-(l-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:10836–40. [PubMed]
51. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379. [PubMed]
52. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 2007;144:950–60. [PMC free article] [PubMed]
53. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331–5. [PubMed]
54. Heininger K. A unifying hypothesis of Alzheimer's disease. IV: causation and sequence of events. Rev Neurosci. 2000;11(Spec No):213–328. [PubMed]
55. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2008 Epub ahead of print. [PubMed]
56. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry. 2005;44:10810–21. [PubMed]